Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aclaris Therapts (ACRS)

Aclaris Therapts (ACRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,014,915
  • Shares Outstanding, K 66,683
  • Annual Sales, $ 6,760 K
  • Annual Income, $ -90,870 K
  • 60-Month Beta 0.55
  • Price/Sales 155.74
  • Price/Cash Flow N/A
  • Price/Book 4.79
Trade ACRS with:

Options Overview Details

View History
  • Implied Volatility 80.14% ( +16.26%)
  • Historical Volatility 62.12%
  • IV Percentile 42%
  • IV Rank 39.52%
  • IV High 158.22% on 05/16/22
  • IV Low 29.11% on 05/23/22
  • Put/Call Vol Ratio 0.07
  • Today's Volume 15
  • Volume Avg (30-Day) 142
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 660
  • Open Int (30-Day) 713

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.46
  • Number of Estimates 5
  • High Estimate -0.44
  • Low Estimate -0.49
  • Prior Year -0.37
  • Growth Rate Est. (year over year) -24.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.90 +6.33%
on 11/03/22
18.96 -16.43%
on 11/16/22
-0.16 (-0.98%)
since 11/01/22
3-Month
12.82 +23.53%
on 09/23/22
18.96 -16.43%
on 11/16/22
-1.38 (-8.00%)
since 09/01/22
52-Week
9.26 +71.09%
on 01/24/22
18.96 -16.43%
on 11/16/22
+3.33 (+26.64%)
since 12/01/21

Most Recent Stories

More News
Philips (PHG) Showcases New AI-Based Solutions at the RSNA

Koninklijke Philips (PHG) banks on its new AI solutions to address issues faced by Radiology experts in the healthcare industry and drive prospects.

PHG : 14.96 (-0.53%)
AGEN : 2.64 (-2.22%)
ABEO : 3.90 (+3.72%)
ACRS : 15.83 (+4.01%)
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of 23.08% and 1,083.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ACRS : 15.83 (+4.01%)
ADXN : 0.7477 (-2.88%)
Aclaris: Q3 Earnings Snapshot

Aclaris: Q3 Earnings Snapshot

ACRS : 15.83 (+4.01%)
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Misses Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of 13.89% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ACRS : 15.83 (+4.01%)
ADXN : 0.7477 (-2.88%)
Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

 •Appointed Douglas Manion, M.D., FRCP (C), as President and COO •Initiated Phase 2a Study Activities for Psoriatic Arthritis    WAYNE, Pa., Aug. 03, 2022...

ACRS : 15.83 (+4.01%)
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 12.20% and 32.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AQST : 0.9410 (+1.18%)
ACRS : 15.83 (+4.01%)
Here's Why Aclaris Therapeutics (ACRS) is a Great Momentum Stock to Buy

Does Aclaris Therapeutics (ACRS) have what it takes to be a top stock pick for momentum investors? Let's find out.

ACRS : 15.83 (+4.01%)
Philips (PHG) Expands AI Portfolio With SmartSpeed Solution

Koninklijke Philips (PHG) announces that its latest AI-powered MR acceleration software SmartSpeed will be showcased as part of the AI-powered precision diagnosis portfolio at ECR.

GE : 85.50 (-0.55%)
PHG : 14.96 (-0.53%)
ABEO : 3.90 (+3.72%)
ACRS : 15.83 (+4.01%)
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?

Here is how Aclaris Therapeutics (ACRS) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.

ACRS : 15.83 (+4.01%)
GTBP : 1.6200 (-1.82%)
Aclaris Therapeutics Expands Leadership Team

Appoints Gail Cawkwell, MD, PhD, as Chief Medical Officer WAYNE, Pa., June 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a...

ACRS : 15.83 (+4.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription...

See More

Key Turning Points

3rd Resistance Point 17.08
2nd Resistance Point 16.62
1st Resistance Point 15.92
Last Price 15.83
1st Support Level 14.77
2nd Support Level 14.31
3rd Support Level 13.61

See More

52-Week High 18.96
Last Price 15.83
Fibonacci 61.8% 15.25
Fibonacci 50% 14.11
Fibonacci 38.2% 12.96
52-Week Low 9.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar